⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2903436 | 0.73 | NOS2 (0.35) | — | |
| SCHEMBL12225903 | 0.73 | — | — | |
| SCHEMBL12343011 | 0.73 | — | — | |
| SCHEMBL13591195 | 0.73 | — | — | |
| SCHEMBL10884677 | 0.73 | — | — | |
| SCHEMBL1828963 | 0.72 | — | — | |
| SCHEMBL27922141 | 0.67 | — | — | |
| SCHEMBL16622933 | 0.67 | — | — | |
| SCHEMBL953315 | 0.67 | — | — | |
| SCHEMBL13840787 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2620429-A1 | Hydroxylamine compounds and methods of their use | Colby Pharmaceutical Company (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-1802297-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE CAUSED BY YERSINIA SPP INFECTION | BURNHAM INST (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20090312352-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE CAUSED BY YERSINIA SPP INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-17 | — | — | US | disclosed |
| EP-2125716-A2 | HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE | Othera Holding, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-2120942-A2 | DRUG RESISTANCE REVERSAL IN NEOPLASTIC DISEASE | Othera Holding, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-7544676-B2 | Sulfamoyl benzamides and methods of their use | ADOLOR CORPORATION (US) | 2009-06-09 | — | — | US | disclosed |
| US-20080280890-A1 | HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE | COLBY PHARMACEUTICAL COMPANY | 2008-11-13 | — | — | US | disclosed |
| WO-2008103613-A2 | HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE | OTHERA HOLDING, INC. (US) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008101195-A2 | DRUG RESISTANCE REVERSAL IN NEOPLASTIC DISEASE | OTHERA HOLDING, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20080200405-A1 | Drug Resistance Reversal In Neoplastic Disease | COLBY PHARMACEUTICAL COMPANY | 2008-08-21 | — | — | US | disclosed |
| WO-2008063625-A2 | PYRIDINE COMPOUNDS AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2008-05-29 | — | — | WO | disclosed |
| EP-1802297-A4 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE CAUSED BY YERSINIA SPP INFECTION | BURNHAM INST (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20080058302-A1 | Sulfamoyl Benzamides and Methods of Their Use | CALIXA THERAPEUTICS, INC. | 2008-03-06 | — | — | US | disclosed |
| US-7297796-B2 | Sulfamoyl benzamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2007-11-20 | — | — | US | disclosed |
| EP-1802297-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE CAUSED BY YERSINIA SPP INFECTION | The Burnham Institute (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2007058960-A1 | SULFAMOYL BENZAMIDES AS CANNABINOID RECEPTOR MODULATORS | ADOLOR CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2006047162-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE CAUSED BY YERSINIA SPP INFECTION | THE BURNHAM INSTITUTE (US) | 2006-05-04 | — | — | WO | disclosed |
| WO-2006044645-A2 | SULFAMOYL BENZAMIDES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060079557-A1 | Sulfamoyl benzamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2006-04-13 | — | — | US | disclosed |